NLRC4 inflammasomopathy with spondyloarthritis and a complete response to TNF inhibition

J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2443-2446.e2. doi: 10.1016/j.jaip.2019.03.028. Epub 2019 Mar 28.

Authors

Mathijs Willemsen¹, Myrurgia Abdul-Hamid², Thea H M Schoonbrood³

Affiliations

¹ Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, the Netherlands. Electronic address: mathijs.willemsen@hotmail.com.
² Department of Pathology, Maastricht University Medical Center, Maastricht, the Netherlands.
³ Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, the Netherlands.

PMID: 30930271
DOI: 10.1016/j.jaip.2019.03.028

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
CARD Signaling Adaptor Proteins / genetics
CARD Signaling Adaptor Proteins / metabolism*
Calcium-Binding Proteins / genetics
Calcium-Binding Proteins / metabolism*
Cryopyrin-Associated Periodic Syndromes / diagnosis*
Cryopyrin-Associated Periodic Syndromes / drug therapy
Cryopyrin-Associated Periodic Syndromes / genetics
Etanercept / therapeutic use*
Female
Humans
Inflammation / diagnosis*
Inflammation / drug therapy
Inflammation / genetics
Interleukin 1 Receptor Antagonist Protein / therapeutic use
Male
Mutation / genetics
Pedigree
Siblings
Spondylitis, Ankylosing / diagnosis*
Spondylitis, Ankylosing / drug therapy
Spondylitis, Ankylosing / genetics
Treatment Outcome
Tumor Necrosis Factor Inhibitors / therapeutic use*

Substances

CARD Signaling Adaptor Proteins
Calcium-Binding Proteins
Interleukin 1 Receptor Antagonist Protein
NLRC4 protein, human
Tumor Necrosis Factor Inhibitors
Etanercept